S-272-119
Passed Senate with an amendment and an amendment to the Title by Unanimous Consent.
Sponsored by Gary Peters (D-MI)
What it does
This bill would require infant formula manufacturers to notify the FDA within one business day of discovering that formula they produced — even if it has already left their facility — may be contaminated, adulterated, or missing required nutrients. It would also require manufacturers to notify the FDA within one business day if testing reveals the presence of dangerous microorganisms such as salmonella, share test results with the FDA promptly, and consult with the FDA on isolating and disposing of affected products. The FDA would be required to respond to such notifications within one business day, determine within 90 days whether a manufacturer has taken appropriate corrective action, and periodically report to Congress on the safety and supply of the infant formula supply chain.
Who benefits
Infants and young children who consume formula, particularly those in households without access to breast milk alternatives. Parents and caregivers who would receive faster public warnings about contaminated products. Pediatricians and healthcare providers who advise families on formula safety. Smaller or regional formula brands that follow safety protocols and may gain competitive advantage over non-compliant manufacturers. Retailers who could face liability for selling recalled products and benefit from faster FDA action. The FDA itself, which would gain earlier access to contamination data.
Who is hurt
Infant formula manufacturers, who would face new compliance costs and tighter reporting timelines, including for contamination discovered before a product leaves their facility — a requirement that goes beyond current law. Larger manufacturers with complex supply chains may face disproportionate administrative burdens. Manufacturers could also face increased legal exposure, as earlier mandatory reporting creates a clearer paper trail in product liability litigation. Taxpayers may bear costs associated with expanded FDA monitoring, reporting, and response obligations, though no specific appropriation is included in the bill.
Supporters argue
Supporters argue that the 2022 Abbott Nutrition plant shutdown — which triggered a nationwide infant formula shortage and exposed serious gaps in FDA oversight — demonstrated that current reporting requirements are dangerously inadequate. Under existing law, manufacturers are only required to report contamination after a product has left their control, meaning the FDA may not learn of an internal contamination finding until a product is already on store shelves. Supporters contend that a one-business-day notification requirement closes this gap, enabling faster recalls and preventing the kind of delayed federal response that left families scrambling for formula for months.
Opponents argue
Opponents argue that the bill imposes rigid, one-size-fits-all timelines that may not account for the complexity of contamination investigations, where preliminary test results can be ambiguous or later disproven. They contend that requiring manufacturers to report unconfirmed findings within one business day could trigger unnecessary public alarm, disrupt supply chains, and incentivize manufacturers to delay internal testing to avoid premature reporting obligations. Critics may also argue that the bill adds procedural mandates on the FDA without providing dedicated funding, potentially straining an agency already managing a broad food safety portfolio.